Education > HIV Clinical Updates
This section includes brief bulletins about topics of interest to those involved in the field of HIV resistance.
Clinical Update #15 - 2008 ICAAC/IDSA Meeting (Release date: Nov. 17, 2008)
Phenotype-based HIV resistance testing provides valuable information to help guide the selection of treatment regimens, particularly in patients with likely resistance to one or more ARVs.
Clinical Update #14 - 2008 International HIV Drug Resistance Workshop (Release date: Jul. 14, 2008)
Phenotypic susceptibility to the first generation NNRTIs (efavirenz and nevirapine) is significantly affected by single mutations in the HIV viral genome.
Clinical Update #13 - 2008 Euro HIV Drug Resistance Workshop (Release date: Jun. 30, 2008)
The emergence of drug-resistant HIV strains is one of the key factors associated with suboptimal virologic response to antiretroviral therapy.
Clinical Update #12 - News from the 24th Annual Clinical Virology Symposium (Release date: Jun. 2, 2008)
The virco®TYPE HIV-1 v4.2.01 (vT) and the PhenoSense GTTM (PSGT) assays use different methods to account for such mixtures in patient samples undergoing evaluation for antiretroviral drug susceptibility.
Clinical Update #11 - A recent study demonstrates accurate prediction of drug susceptibility from viral genotype (Release date: May 27, 2008)
The VirtualPhenotypeTM-LM is a data-driven linear-regression modeling engine that provides an accurate prediction of the HIV resistance phenotype from the viral genotype.
Clinical Update #10 - News from the 6th European HIV Drug Resistance Workshop (Release date: May 10, 2008)
The interpretation of quantitative phenotypic resistance information via clinical cut-off values on the virco®TYPE HIV-1 report can assist HIV providers in optimizing combination antiretroviral therapy.
Clinical Update #9 - News from the 15th Conference on Retroviruses and Opportunistic Infections (Release date: Mar. 3, 2008)
Etravirine (TMC125), a new next-generation NNRTI, shows antiviral activity in treatment-experienced adult patients with HIV resistant to a NNRTI and other antiretroviral agents.
Clinical Update #8 - News from the 15th Conference on Retroviruses and Opportunistic Infections (Release date: Feb. 18, 2008)
Bart Winters and colleagues from Virco, presented data at the 15th Conference on Retroviruses and Opportunistic Infections on the development of vircoŽTYPE HIV-1 clinical cut-off values for etravirine based on treatment response data from etravirine phase II/III studies.
Clinical Update #7 - News from the latest update to the virco®TYPE-HIV-1 report, version 4.2.01. (Release date: Jan. 31, 2008)
The virco®TYPE-HIV-1 report is the first resistance report to have a resistance call for INTELENCE™ and list the relevant mutations.
Clinical Update #6 - News from the 45th Annual Meeting of the Infectious Diseases Society of America (Release date: Dec. 03, 2007)
Current guidelines recommend the use of resistance tests to optimize the selection of active regimens when initiating or changing antiretroviral therapy.
Clinical Update #5 - News from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Release date: Sep. 26, 2007)
Earlier studies using a limited number of laboratory and clinical isolates demonstrated that the HIV-1 protease mutation I50L confers resistance to atazanavir and susceptibility to other protease inhibitors (PIs).
Clinical Update #4 - News from the 16th International HIV Drug Resistance Workshop (Release date: Sep. 06, 2007)
An important aspect of the development of any system that predicts response to antiretroviral therapy is its validation in a diverse clinical dataset not used for algorithm development.
Clinical Update #3 - News from the 23rd Clinical Virology Symposium (Release date: May. 24, 2007)
Karam Mounzer and colleagues from The Jonathan Lax Treatment Center, in collaboration with Virco, presented a poster at the 23rd Annual Clinical Virology Symposium evaluating concordance of drug-specific resistance in PhenoSense GTTM (PGT) and virco®TYPE HIV-1 (virtual phenotype, VP) and estimated the cost savings associated with introduction of VP assays into a community-based clinic.
Clinical Update #2 - News from the 5th European HIV Drug Resistance Workshop (Release date: May. 17, 2007)
The 5th European HIV Drug Resistance Workshop featured 7 important scientific contributions by researchers at Virco Labs.
Clinical Update #1 - News from 14th Annual CROI Meeting (Release date: Apr. 16, 2007)
Bart Winters and colleagues from Virco presented a poster at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) which described the development of linear regression models (LM) used to predict fold change (FC) values for atazanavir (ATV) and fos-amprenavir (FPV) from genotypic sequences and the establishment of clinical cut-offs (CCO) for ritonavir-boosted atazanavir (ATV/r) and ritonavir-boosted fosamprenavir (FPV/r). This study was done in collaboration with GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS), and other external investigators.
